GILEAD SCIENCES, INC.

GILDNasdaq

Biological Products, (No Diagnostic Substances)CIK 0000882095Live· source checked 4m oldlatest filing 2026-07-16

As-filed data from SEC EDGAR (US-government public domain). No market quotes on this page — filings and fundamentals only.

The information on this page is market data and educational analysis, not financial advice. Past on-chain activity does not guarantee future results. Always do your own research.

Annual fundamentals — as filed

Revenue

$29.4B

FY2025 · period ended 2025-12-31 · 10-K · SEC EDGAR

Net income

$8.5B

FY2025 · period ended 2025-12-31 · 10-K · SEC EDGAR

Total assets

$59.0B

FY2025 · period ended 2025-12-31 · 10-K · SEC EDGAR

Stockholders' equity

$22.7B

FY2025 · period ended 2025-12-31 · 10-K · SEC EDGAR

Recent filings

144filed 2026-07-15View on SEC.gov
144filed 2026-07-15View on SEC.gov
144filed 2026-06-15View on SEC.gov
144filed 2026-06-15View on SEC.gov
144filed 2026-06-01View on SEC.gov

Insider forms (3 / 4 / 5)

Statements of beneficial ownership filed by officers, directors and 10%+ owners. A filing documents a reported change — it is not a buy or sell signal.

Form 4filed 2026-07-16View on SEC.gov
Form 4filed 2026-07-16View on SEC.gov
Form 4filed 2026-07-02View on SEC.gov
Form 4filed 2026-06-16View on SEC.gov
Form 4filed 2026-06-16View on SEC.gov

Source: SEC EDGAR, as-filed documents (public domain). Figures are annual XBRL facts from the latest 10-K; no adjustments applied. Educational information only — not financial advice.